TGF-beta-specific antibodies and methods of use thereof for treatment
View Patent ↗The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.
1. An antibody that competes with reference antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising
(a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 19;
(b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 20;
(c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 21;
(d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 22;
(e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 23; and
(f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 24,
wherein the competing antibody also binds to TGF-β1, TGFβ2 and TGFβ3.
2. An antibody that competes with reference antibody having
(a) a heavy chain variable region comprising at least a CDR1 amino acid sequence set out in SEQ ID NO: 19, a CDR2 amino acid sequence set out in SEQ ID NO: 20, and a CDR3 amino acid sequence set out in SEQ ID NO: 21; and
(b) a light chain variable region comprising at least a CDR1 amino acid sequence set out in SEQ ID NO: 22, a CDR2 amino acid sequence set out in SEQ ID NO: 23, and a CDR3 amino acid sequence set out in SEQ ID NO: 24,
for binding to transforming growth factor beta (TGF-β)1, TGFβ2 and TGFβ3.
3. The antibody of claim 2 , wherein the reference antibody that binds TGFβ1, TGFβ2 and TGFβ3 comprises a heavy chain variable region amino acid sequence set out in SEQ ID NO: 6 and a light chain variable region amino acid sequence set out in SEQ ID NO: 8.
4. The antibody of claim 2 that binds TGFβ1 and TGFβ2 with an affinity between a Kd of 10 −6 to 10 −12 M.
5. The antibody of claim 2 , wherein the antibody binds to TGFβ1 and TGFβ2 with greater affinity than it does to TGFβ3.
6. The antibody of claim 2 , wherein the antibody neutralizes activity of TGFβ1 and TGFβ2 to a greater extent than it does to TGFβ3.
7. The antibody of claim 2 , in which one or more heavy chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.
8. The antibody of claim 2 , further comprising a heavy chain constant region, wherein the heavy chain constant region is a modified or unmodified IgG, IgM, IgA, IgD, IgE, a fragment thereof, or combinations thereof.
9. The antibody of claim 2 , in which one or more light chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.
10. A sterile pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.
11. A method for treating a disease, condition or disorder associated with TGFβ expression comprising the step of administering to a subject in need thereof a therapeutically effective amount of the antibody of claim 2 or the pharmaceutical composition of claim 10 .
12. A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the antibody of claim 2 or the pharmaceutical composition of claim 10 .
13. The method of claim 12 , wherein the antibody or composition increases the number of natural killer (NK) cells in a tumor and/or improves NK cell cytolytic activity.
14. The method of claim 12 , wherein the antibody or composition decreases the number of regulatory T cells in a tumor and/or inhibits regulatory T cell function.
15. The method of claim 12 , wherein the antibody or composition increases the number of cytotoxic T cells (CTLs) in a tumor and/or enhances CTL function.
16. The method of claim 12 , wherein the antibody decreases the number of myeloid-derived suppressor cells (MDSC) in a tumor and/or inhibits MDSC function.
17. The method of claim 12 , wherein the antibody decreases the number of dendritic cells (DC) in a tumor and/or inhibits the tolerogenic function of dendritic cells.
18. The method of claim 12 , wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma.
19. The method of claim 18 wherein the cancer is melanoma.
20. A method for treating fibrosis comprising administering to a subject in need thereof a therapeutically effective amount of the antibody of claim 2 or the pharmaceutical composition of claim 10 .